

1ST NEWSLETTER IMMUNOSEP STUDY

Dear Investigators,


We start this series of Newsletters to keep you updated with the progress of the ImmunoSep trial

Current progress (as of 3 April 2022):

- 20 sites activated
- 112 patients screened
- 47 patients randomized

Our final Goal: 280 patients randomized by April 2023

MONTHLY PROGRESS



MALS: macrophage activation-like syndrome

SITE PROGRESS

Centre	# Screened subjects	# Enrolment Subjects
4 th Department of Internal Medicine, ATTIKON University Hospital, Athens	17	4
2 nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens	17	13
Intensive Care Unit, "Ippokrateion" Thessaloniki General Hospital	15	6
Intensive Care Unit, "Aghios Dimitrios" Thessaloniki General Hospital	15	6
Intensive Care Unit, "KAT" General Hospital of Attika, Athens	15	7
Intensive Care Unit, "Theageneio" Thessaloniki Anticancer Hospital	9	4
Latsio Intensive Care Unit, "Thrasio" Elefsis General Hospital	7	1
Intensive Care Unit, "AHEPA" Thessaloniki University General Hospital	6	3
Intensive Care Unit, "G.Gennimatas" Thessaloniki General Hospital	3	1
2 nd Department of Propaedeutic Internal Medicine, ATTIKON University Hospital, Athens	2	1
Intensive Care Unit, Ioannina University General Hospital	2	0
1 st Department of Pulmonary Medicine and Intensive Care Unit, SOTIRIA General Hospital of Chest Diseases of Athens, Athens	1	0
Department of Internal Medicine, Larissa University General Hospital	1	1
Intensive Care Unit, "Koutlimbaneio & Triantafylleio" Larissa General Hospital	1	1
Intensive Care Unit, "Tzaneio" Piraeus General Hospital	1	1
5 th Department of Internal Medicine, "Evangelismos" General Hospital of Athens	0	0
3 rd Department of Internal Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens	0	0
Department of Internal Medicine and Infectious Diseases, Amsterdam Medical Centre	0	0
Intensive Care Unit University Medical Center Radboud, Nijmegen	0	0
Intensive Care Unit, Alexandroupolis University General Hospital	0	0
TOTAL	112	47
<u>Sites to become soon activated</u>		
Multipurpose Intensive Care Unit, SOTIRIA General Hospital of Chest Diseases of Athens, Athens		
424 General Military Hospital Intensive Care Unit, Thessaloniki		
<u>Sites with pending approval</u>		
Department of Internal Medicine and Infectious Diseases, Centre Hospitaliaire Universitaire Vaudois, Lausanne		
Intensive Care Unit, Jena University Hospital		
Department of Internal Medicine and Infectious Diseases, Cluj-Napoca		

Congratulations to Our Pioneers for 2022

Centre	# Screened subjects	# Enrolment Subjects
Intensive Care Unit, "KAT" General Hospital of Attiki, Athens (PI: I. Alamanos)	15	7
Intensive Care Unit, "Ippokrateion" Thessaloniki General Hospital (PI: E.Mouloudi)	14	6
4 th Department of Internal Medicine, ATTIKON University Hospital, Athens (PI: A. Papadopoulos)	12	2
Intensive Care Unit, "Aghios Dimitrios" Thessaloniki General Hospital (PI: G. Vlachogianni)	10	4
Intensive Care Unit, "Theageneio" Thessaloniki Anticancer Hospital (PI: S. Anisoglou)	9	4

Useful tips to remember

INCLUSION CRITERIA

- Both COVID-19 and non-COVID-19 may be enrolled
- COVID-19 Patients *without* secondary VAP/HAP/BSI are enrolled ONLY if they have MALS
- COVID-19 Patients *with* secondary VAP/HAP/BSI are enrolled as ALL other patients

Useful tips to remember

- 10-day dexamethasone course does NOT exclude the patient
- Treatments with Tocilizumab, Anakinra and Baricitinib do NOT exclude the patient

BSI: bloodstream infection
 CAP: community-acquired pneumonia
 HAP: hospital-acquired pneumonia
 MALS: macrophage activation-like syndrome

Please continue to update the eCRF daily

A warm thank you

To all Investigators and study team members for your contribution so far! We appreciate your continued commitment to this study!